{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:35:16Z","timestamp":1794198916626,"version":"4.8.0"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T00:00:00Z","timestamp":1543708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Antiviral drugs can play a significant role in the control of influenza. Umifenovir (Arbidol) is licensed and widely used in Russia for the prophylaxis and\/or treatment of influenza. We evaluated the susceptibility to umifenovir of reference influenza A and B viruses and influenza A viruses isolated from patients in the ARBITR clinical trial in 2012\u20102014 seasons. Using an MDCK cell\u2010based enzyme\u2010linked immunosorbent assay (ELISA), we showed that the replication of antigenically dominant human influenza A and B viruses was efficiently inhibited by umifenovir. The wild\u2010type \u0410\/Perth\/265\/2009 (H1N1)pdm09, A\/Fukui\/45\/2004 (H3N2), and B\/Perth\/211\/2001 viruses and their oseltamivir\u2010resistant counterparts were susceptible to umifenovir among in vitro laboratory assays. All 18 clinical isolates of influenza A viruses obtained before and during therapy were susceptible to umifenovir with 50% effective concentration (EC\n<jats:sub>50<\/jats:sub>) ranging from 8.4\u2009\u00b1\u20091.1 to 17.4\u2009\u00b1\u20095.4\u2009\u00b5M. No molecular markers of umifenovir resistance were identified in influenza viruses isolate d from patients at 3, 5, and 7 days after initiation of therapy. None of the viruses isolated before and during umifenovir therapy displayed reduced susceptibility to neuraminidase (NA) inhibitors. Thus, umifenovir is effective against influenza viruses circulating in 2012\u20102014 seasons, and therapy did not lead to the emergence of drug\u2010resistant variants.<\/jats:p>","DOI":"10.1002\/jmv.25358","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T22:40:52Z","timestamp":1542321652000},"page":"588-597","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study"],"prefix":"10.1002","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7755-2714","authenticated-orcid":false,"given":"Irina A.","family":"Leneva","sequence":"first","affiliation":[{"name":"Department of Experimental Virology, I. Mechnikov Research Institute for Vaccines and Sera Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina N.","family":"Falynskova","sequence":"additional","affiliation":[{"name":"Department of Experimental Virology, I. Mechnikov Research Institute for Vaccines and Sera Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nailya R.","family":"Makhmudova","sequence":"additional","affiliation":[{"name":"Department of Experimental Virology, I. Mechnikov Research Institute for Vaccines and Sera Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2004-3935","authenticated-orcid":false,"given":"Artem A.","family":"Poromov","sequence":"additional","affiliation":[{"name":"Department of Experimental Virology, I. Mechnikov Research Institute for Vaccines and Sera Moscow Russia"},{"name":"Department of General Ecology, Lomonosov Moscow State University Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana B.","family":"Yatsyshina","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnostic and Epidemiology, Central Research Institute for Epidemiology Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor V.","family":"Maleev","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnostic and Epidemiology, Central Research Institute for Epidemiology Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,2]]},"reference":[{"key":"e_1_2_7_1_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068030"},{"key":"e_1_2_7_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2014.04.009"},{"key":"e_1_2_7_1_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/363418a0"},{"key":"e_1_2_7_1_5_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja963036t"},{"key":"e_1_2_7_1_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.13.1240"},{"key":"e_1_2_7_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02288-1"},{"key":"e_1_2_7_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16934-1"},{"key":"e_1_2_7_1_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/596311"},{"key":"e_1_2_7_1_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/v7092850"},{"key":"e_1_2_7_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.02.003"},{"key":"e_1_2_7_1_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04836-14"},{"key":"e_1_2_7_1_13_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2014.19.1.20666"},{"key":"e_1_2_7_1_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-015-0317-1"},{"key":"e_1_2_7_1_15_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2101.141006"},{"key":"e_1_2_7_1_16_1","unstructured":"Toyama Chemical Co. L. The new drug application approval of \u201cAVIGAN\u00ae Tablet 200mg\u201d in Japan for the anti\u2010influenza virus drug.2014."},{"key":"e_1_2_7_1_17_1","unstructured":"Shionogi & Co. Ltd. XOFLUZA (Baloxavir Marboxil) tablets 10mg\/20 mg approved for the treatment of influenza types A and B In Japan.2018:1."},{"key":"e_1_2_7_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.06.007"},{"key":"e_1_2_7_1_19_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.14156SC"},{"key":"e_1_2_7_1_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27890-4"},{"key":"e_1_2_7_1_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00430-18"},{"key":"e_1_2_7_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2008.10.009"},{"key":"e_1_2_7_1_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617020114"},{"key":"e_1_2_7_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.01.001"},{"issue":"2","key":"e_1_2_7_1_25_1","first-page":"24","article-title":"Rimantadine and arbidol sensitivity of influenza viruses that caused epidemic morbidity rise in Russia in the 2004\u20102005 season","volume":"52","author":"Burtseva EI","year":"2007","journal-title":"Vopr Virusol"},{"issue":"3","key":"e_1_2_7_1_26_1","first-page":"3","article-title":"Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture","volume":"56","author":"Fediakina IT","year":"2011","journal-title":"Antibiot i khimioterapiia=Antibiot chemoterapy [sic]"},{"key":"e_1_2_7_1_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986708784049658"},{"issue":"3","key":"e_1_2_7_1_28_1","first-page":"289","article-title":"Efficacy and safety of arbidol in treatment of naturally acquired influenza","volume":"26","author":"Wang MZ","year":"2004","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"e_1_2_7_1_29_1","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201789162-71"},{"key":"e_1_2_7_1_30_1","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201587188-96"},{"key":"e_1_2_7_1_31_1","first-page":"97p","article-title":"World Health Organization","author":"Webster RG","year":"2002","journal-title":"WHO Manual on Animal Influenza Diagnosis and Surveillance"},{"key":"e_1_2_7_1_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(92)91187-Y"},{"key":"e_1_2_7_1_33_1","article-title":"Standard operating procedure WHO\u2010025: fluorometric neuraminidase inhibition assay. Official copy","author":"Hurt A","year":"2007","journal-title":"World Heal Organ Collab Cent Ref Res Influ Aust"},{"issue":"12","key":"e_1_2_7_1_34_1","first-page":"1","article-title":"Dose\u2010response analysis using R","volume":"10","author":"Ritz C","year":"2016","journal-title":"PLoS One"},{"key":"e_1_2_7_1_35_1","unstructured":"Review of the 2012\u20132013 winter influenza season northern hemisphere. Weekly epidemiological record.World Heal Organ.2013;22(88):225\u2013232."},{"key":"e_1_2_7_1_36_1","unstructured":"Review of the 2013\u20132014 winter influenza season northern hemisphere. Weekly epidemiological record.World Heal Organ.2014;(23):245\u2010256."},{"key":"e_1_2_7_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.04.006"},{"key":"e_1_2_7_1_38_1","first-page":"4","article-title":"Study of arbidol, a new anti\u2010influenzal drug, using immuno\u2010enzymated detection of virus specific antigens","volume":"9","author":"Leneva IA","year":"1994","journal-title":"Chem Pharm J"},{"key":"e_1_2_7_1_39_1","first-page":"470","article-title":"Monitoring and characterization of oseltamivir\u2010resistant pandemic (H1N1) 2009 virus, Japan, 2009\u20132010","volume":"17","author":"Ujike M","year":"2011","journal-title":"Emerg Infect Dis. 2011;17(3):470\u2010479"},{"key":"e_1_2_7_1_40_1","doi-asserted-by":"publisher","DOI":"10.1086\/318537"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.25358","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25358","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T07:52:49Z","timestamp":1694332369000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.25358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,2]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1002\/jmv.25358"],"URL":"https:\/\/doi.org\/10.1002\/jmv.25358","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,2]]},"assertion":[{"value":"2018-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}